A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...
FRANKFURT, March 9 (Reuters) - Roche's shares dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...
Ipsen will withdraw Tazverik’s follicular lymphoma and epithelioid sarcoma indications as emerging data point to an elevated ...
Wall Street's verdict on Prasad, generic semaglutide's new pricing, and other biotech news ...
The cancer drug tazemetostat (Tazverik) is being voluntarily withdrawn in the U.S. and all other markets over concerns about secondary cancers, drugmaker Ipsen announced. The company also said it is ...
Surgeon Gareth Honeybone wants wider access to zanidatamab to treat one of the deadliest cancers.
Neuroscientists at King's College London have pinpointed a mechanism behind the increased neural connectivity observed in the ...
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
News-Medical.Net on MSN
Taking anticoagulants alongside prostate cancer drugs does not increase bleeding risk
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its promising drug candidate ...
Roche said the late-stage trial did not provide reliable evidence that the drug's use in combination with Pfizer's Ibrance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results